Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for MDGL

Stock Name	Madrigal Pharmaceuticals Inc
Ticker	MDGL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5588681057
LEI	549300CHIMT2EUSNJB60

Show aggregate MDGL holdings

News associated with MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $483.38 Consensus Target Price from Brokerages: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […] - 2025-09-17 02:42:46
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and BioNxt Solutions (OTCMKTS:BNXTF): Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Madrigal Pharmaceuticals and BioNxt […] - 2025-08-28 04:46:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-08-20 03:12:44
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Insider Selling: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $369.84, but opened at $354.56. Madrigal Pharmaceuticals shares last traded at $364.21, with a volume of 83,865 shares changing hands. Specifically, General Counsel Shannon T. Kelley sold […] - 2025-08-20 02:17:00
Stocks Mixed Before Trump-Zelenskiy Meeting and Retailer Earnings: The S&P 500 Index ($SPX ) (SPY ) today is down by -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.09%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September... - 2025-08-18 14:26:35
Stocks Slightly Lower on Concern Over Progress to End Russian-Ukrainian War: The S&P 500 Index ($SPX ) (SPY ) today is down by -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.17%. September E-mini S&P futures (ESU25 ) are down -0.06%, and September... - 2025-08-18 12:43:44
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $3,652,000.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Kenneth Bate sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director owned 2,627 shares of the company’s stock, […] - 2025-08-18 05:18:50
Cetera Investment Advisers Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Cetera Investment Advisers reduced its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,832 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Cetera Investment Advisers’ holdings in Madrigal Pharmaceuticals were worth $938,000 as of its […] - 2025-08-13 04:49:04
1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Blair William & Co. IL: Blair William & Co. IL bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $332,000. Other hedge funds also […] - 2025-08-12 05:00:47
Zurcher Kantonalbank Zurich Cantonalbank Sells 291 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Zurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 2,138 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Madrigal Pharmaceuticals were worth $708,000 as of […] - 2025-08-07 04:26:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up on Strong Earnings: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $312.11, but opened at $350.00. Madrigal Pharmaceuticals shares last traded at $330.70, with a volume of 156,412 shares traded. The biopharmaceutical company reported ($1.90) […] - 2025-08-07 02:12:57
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 1,000 Shares of Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Rebecca Taub sold 1,000 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the transaction, the director owned 461,044 shares in the company, valued at $161,365,400. […] - 2025-07-24 05:51:01
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $490,042.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 1,400 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 […] - 2025-07-24 05:50:51
New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): New York State Common Retirement Fund lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 […] - 2025-07-18 06:22:45
Mutual of America Capital Management LLC Boosts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Mutual of America Capital Management LLC grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,263 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during […] - 2025-07-18 05:49:00
D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): D.A. Davidson & CO. grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 203.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,458 shares during the period. D.A. Davidson & CO.’s […] - 2025-07-10 05:25:03
First Horizon Advisors Inc. Grows Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 38.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 157 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the period. First Horizon Advisors Inc.’s […] - 2025-07-08 05:08:55
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $420.63 Consensus Price Target from Analysts: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The […] - 2025-07-04 02:40:48
QRG Capital Management Inc. Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 726 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. Other institutional investors also recently bought and sold shares of the company. […] - 2025-06-24 04:42:49
Head-To-Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Larimar Therapeutics (NASDAQ:LRMR): Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Larimar Therapeutics and Madrigal […] - 2025-06-12 03:09:35
Wellington Management Group LLP Has $2.52 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Wellington Management Group LLP lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,172 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. Wellington Management Group LLP’s holdings […] - 2025-06-06 05:04:52
Analysts Anticipate 12% Upside For The Holdings of AVLC: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:37:18
Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) and Adicet Bio (NASDAQ:ACET): Adicet Bio (NASDAQ:ACET – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Volatility & Risk Adicet Bio has a beta […] - 2025-05-21 03:01:02
MDGL Crosses Below Key Moving Average Level: In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal Pharmaceuticals Inc shares are currently trading down about 2.5% on the day. The chart bel - 2025-05-14 12:56:35
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 06:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 04:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC: Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 05:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 05:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC: Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 05:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 04:20:54

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) MDGL holdings

Date	Number of MDGL Shares Held	Base Market Value of MDGL Shares	Local Market Value of MDGL Shares	Change in MDGL Shares Held	Change in MDGL Base Value	Current Price per MDGL Share Held	Previous Price per MDGL Share Held
2025-12-03 (Wednesday)	15,685	USD 9,095,575	USD 9,095,575	87	USD 155,581	USD 579.89	USD 573.15
2025-12-02 (Tuesday)	15,598	USD 8,939,994	USD 8,939,994	555	USD 223,328	USD 573.15	USD 579.45
2025-12-01 (Monday)	15,043	USD 8,716,666	USD 8,716,666	0	USD -263,704	USD 579.45	USD 596.98
2025-11-28 (Friday)	15,043	USD 8,980,370	USD 8,980,370	37	USD -38,686	USD 596.98	USD 601.03
2025-11-27 (Thursday)	15,006	USD 9,019,056	USD 9,019,056	0	USD 0	USD 601.03	USD 601.03
2025-11-26 (Wednesday)	15,006	USD 9,019,056	USD 9,019,056	111	USD 200,620	USD 601.03	USD 592.04
2025-11-25 (Tuesday)	14,895	USD 8,818,436	USD 8,818,436	185	USD 170,133	USD 592.04	USD 587.92
2025-11-24 (Monday)	14,710	USD 8,648,303	USD 8,648,303	37	USD 608,086	USD 587.92	USD 547.96
2025-11-21 (Friday)	14,673	USD 8,040,217	USD 8,040,217	0	USD 85,690	USD 547.96	USD 542.12
2025-11-20 (Thursday)	14,673	USD 7,954,527	USD 7,954,527	-148	USD -280,021	USD 542.12	USD 555.6
2025-11-19 (Wednesday)	14,821	USD 8,234,548	USD 8,234,548	37	USD -29,560	USD 555.6	USD 558.99
2025-11-18 (Tuesday)	14,784	USD 8,264,108	USD 8,264,108	222	USD 205,206	USD 558.99	USD 553.42
2025-11-17 (Monday)	14,562	USD 8,058,902	USD 8,058,902	74	USD 391,708	USD 553.42	USD 529.21

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MDGL by Blackrock for IE00BDZVHG35

Show aggregate share trades of MDGL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 BUY 87 592.880 570.500 572.738 USD 49,828 348.68
2025-12-02 BUY 555 598.770 569.040 572.013 USD 317,467 347.56
2025-11-28 BUY 37 605.000 590.560 592.004 USD 21,904 345.16
2025-11-26 BUY 111 604.590 585.094 587.044 USD 65,162 342.57
2025-11-26 BUY 111 604.590 585.094 587.044 USD 65,162 342.57
2025-11-25 BUY 185 594.460 566.990 569.737 USD 105,401 341.31
2025-11-24 BUY 37 594.990 545.000 549.999 USD 20,350 340.05
2025-11-20 SELL -148 571.120 540.010 543.121 USD -80,382 337.94 Loss of -30,367 on sale
2025-11-19 BUY 37 570.240 553.235 554.935 USD 20,533 336.81
2025-11-18 BUY 222 577.900 545.380 548.632 USD 121,796 335.65
2025-11-17 BUY 74 555.120 520.450 523.917 USD 38,770 334.51
2025-11-14 BUY 37 534.950 505.000 507.995 USD 18,796 333.49
2025-11-12 BUY 37 542.190 520.000 522.219 USD 19,322 331.48
2025-11-10 BUY 37 505.050 486.250 488.130 USD 18,061 329.47
2025-11-06 BUY 37 491.910 471.220 473.289 USD 17,512 327.73
2025-11-04 BUY 37 469.950 405.000 411.495 USD 15,225 326.28
2025-10-30 BUY 185 434.980 420.505 421.953 USD 78,061 324.71
2025-10-29 BUY 74 421.600 434.482 433.194 USD 32,056 324.17
2025-10-22 SELL -148 415.950 430.250 428.820 USD -63,465 321.25 Loss of -15,921 on sale
2025-10-20 BUY 74 439.970 442.970 442.670 USD 32,758 319.92
2025-10-17 BUY 185 438.900 440.170 440.043 USD 81,408 319.22
2025-10-15 BUY 296 433.450 451.410 449.614 USD 133,086 318.54
2025-10-03 BUY 259 443.010 453.580 452.523 USD 117,203 317.09
2025-10-02 BUY 37 449.640 462.880 461.556 USD 17,078 316.29
2025-09-30 BUY 74 458.660 460.220 460.064 USD 34,045 314.61
2025-09-26 BUY 74 424.230 428.250 427.848 USD 31,661 313.14
2025-09-25 BUY 74 422.990 429.130 428.516 USD 31,710 312.46
2025-09-18 BUY 38 440.750 444.270 443.918 USD 16,869 311.66
2025-09-17 BUY 114 417.430 431.500 430.093 USD 49,031 310.99
2025-07-17 SELL -76 348.730 352.000 351.673 USD -26,727 309.72 Loss of -3,188 on sale
2025-07-16 BUY 129 344.970 357.910 356.616 USD 46,003 309.49
2025-07-11 SELL -304 315.460 316.960 316.810 USD -96,310 309.37 Loss of -2,261 on sale
2025-07-02 BUY 2,090 300.150 311.210 310.104 USD 648,117 309.48
2025-06-25 BUY 76 277.640 284.990 284.255 USD 21,603 309.88
2025-06-20 BUY 386 285.730 287.850 287.638 USD 111,028 310.42
2025-06-11 BUY 74 294.340 300.940 300.280 USD 22,221 311.59
2025-06-10 BUY 74 282.320 287.560 287.036 USD 21,241 311.81
2025-06-04 SELL -37 279.320 288.290 287.393 USD -10,634 312.87 Profit of 943 on sale
2025-04-23 BUY 37 308.790 316.180 315.441 USD 11,671 318.09
2025-04-10 SELL -296 307.350 313.000 312.435 USD -92,481 319.05 Profit of 1,959 on sale
2025-04-08 SELL -37 302.780 325.810 323.507 USD -11,970 319.30 Loss of -156 on sale
2025-04-07 SELL -37 310.520 321.590 320.483 USD -11,858 319.40 Loss of -40 on sale
2025-04-04 SELL -185 314.390 325.080 324.011 USD -59,942 319.46 Loss of -842 on sale
2025-04-01 BUY 318 323.980 334.930 333.835 USD 106,160 319.22
2025-03-31 SELL -108 331.230 333.000 332.823 USD -35,945 319.08 Loss of -1,485 on sale
2025-03-21 BUY 597 341.620 344.190 343.933 USD 205,328 317.55
2025-03-14 SELL -544 348.350 348.350 348.350 USD -189,502 315.90 Loss of -17,654 on sale
2025-03-07 SELL -68 331.410 339.080 338.313 USD -23,005 314.89 Loss of -1,593 on sale
2025-03-04 SELL -34 321.320 327.880 327.224 USD -11,126 314.05 Loss of -448 on sale
2025-02-25 BUY 68 309.490 320.540 319.435 USD 21,722 312.57
2025-02-19 SELL -34 343.630 344.060 344.017 USD -11,697 310.67 Loss of -1,134 on sale
2025-02-13 BUY 102 351.710 352.990 352.862 USD 35,992 308.21
2025-02-12 BUY 34 340.170 340.180 340.179 USD 11,566 307.55
2025-02-11 BUY 136 331.790 336.710 336.218 USD 45,726 307.05
2024-12-30 SELL -1,160 311.620 315.270 314.905 USD -365,290 297.51 Loss of -20,174 on sale
2024-11-18 SELL -555 303.490 308.430 307.936 USD -170,904 269.37 Loss of -21,401 on sale
2024-11-08 SELL -37 350.700 357.050 356.415 USD -13,187 258.59 Loss of -3,620 on sale
2024-10-21 SELL -37 208.890 213.020 212.607 USD -7,866 0.00 Loss of -7,866 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	BUY	87	592.880	570.500	572.738	USD 49,828	348.68
2025-12-02	BUY	555	598.770	569.040	572.013	USD 317,467	347.56
2025-11-28	BUY	37	605.000	590.560	592.004	USD 21,904	345.16
2025-11-26	BUY	111	604.590	585.094	587.044	USD 65,162	342.57
2025-11-26	BUY	111	604.590	585.094	587.044	USD 65,162	342.57
2025-11-25	BUY	185	594.460	566.990	569.737	USD 105,401	341.31
2025-11-24	BUY	37	594.990	545.000	549.999	USD 20,350	340.05
2025-11-20	SELL	-148	571.120	540.010	543.121	USD -80,382	337.94 Loss of -30,367 on sale
2025-11-19	BUY	37	570.240	553.235	554.935	USD 20,533	336.81
2025-11-18	BUY	222	577.900	545.380	548.632	USD 121,796	335.65
2025-11-17	BUY	74	555.120	520.450	523.917	USD 38,770	334.51
2025-11-14	BUY	37	534.950	505.000	507.995	USD 18,796	333.49
2025-11-12	BUY	37	542.190	520.000	522.219	USD 19,322	331.48
2025-11-10	BUY	37	505.050	486.250	488.130	USD 18,061	329.47
2025-11-06	BUY	37	491.910	471.220	473.289	USD 17,512	327.73
2025-11-04	BUY	37	469.950	405.000	411.495	USD 15,225	326.28
2025-10-30	BUY	185	434.980	420.505	421.953	USD 78,061	324.71
2025-10-29	BUY	74	421.600	434.482	433.194	USD 32,056	324.17
2025-10-22	SELL	-148	415.950	430.250	428.820	USD -63,465	321.25 Loss of -15,921 on sale
2025-10-20	BUY	74	439.970	442.970	442.670	USD 32,758	319.92
2025-10-17	BUY	185	438.900	440.170	440.043	USD 81,408	319.22
2025-10-15	BUY	296	433.450	451.410	449.614	USD 133,086	318.54
2025-10-03	BUY	259	443.010	453.580	452.523	USD 117,203	317.09
2025-10-02	BUY	37	449.640	462.880	461.556	USD 17,078	316.29
2025-09-30	BUY	74	458.660	460.220	460.064	USD 34,045	314.61
2025-09-26	BUY	74	424.230	428.250	427.848	USD 31,661	313.14
2025-09-25	BUY	74	422.990	429.130	428.516	USD 31,710	312.46
2025-09-18	BUY	38	440.750	444.270	443.918	USD 16,869	311.66
2025-09-17	BUY	114	417.430	431.500	430.093	USD 49,031	310.99
2025-07-17	SELL	-76	348.730	352.000	351.673	USD -26,727	309.72 Loss of -3,188 on sale
2025-07-16	BUY	129	344.970	357.910	356.616	USD 46,003	309.49
2025-07-11	SELL	-304	315.460	316.960	316.810	USD -96,310	309.37 Loss of -2,261 on sale
2025-07-02	BUY	2,090	300.150	311.210	310.104	USD 648,117	309.48
2025-06-25	BUY	76	277.640	284.990	284.255	USD 21,603	309.88
2025-06-20	BUY	386	285.730	287.850	287.638	USD 111,028	310.42
2025-06-11	BUY	74	294.340	300.940	300.280	USD 22,221	311.59
2025-06-10	BUY	74	282.320	287.560	287.036	USD 21,241	311.81
2025-06-04	SELL	-37	279.320	288.290	287.393	USD -10,634	312.87 Profit of 943 on sale
2025-04-23	BUY	37	308.790	316.180	315.441	USD 11,671	318.09
2025-04-10	SELL	-296	307.350	313.000	312.435	USD -92,481	319.05 Profit of 1,959 on sale
2025-04-08	SELL	-37	302.780	325.810	323.507	USD -11,970	319.30 Loss of -156 on sale
2025-04-07	SELL	-37	310.520	321.590	320.483	USD -11,858	319.40 Loss of -40 on sale
2025-04-04	SELL	-185	314.390	325.080	324.011	USD -59,942	319.46 Loss of -842 on sale
2025-04-01	BUY	318	323.980	334.930	333.835	USD 106,160	319.22
2025-03-31	SELL	-108	331.230	333.000	332.823	USD -35,945	319.08 Loss of -1,485 on sale
2025-03-21	BUY	597	341.620	344.190	343.933	USD 205,328	317.55
2025-03-14	SELL	-544	348.350	348.350	348.350	USD -189,502	315.90 Loss of -17,654 on sale
2025-03-07	SELL	-68	331.410	339.080	338.313	USD -23,005	314.89 Loss of -1,593 on sale
2025-03-04	SELL	-34	321.320	327.880	327.224	USD -11,126	314.05 Loss of -448 on sale
2025-02-25	BUY	68	309.490	320.540	319.435	USD 21,722	312.57
2025-02-19	SELL	-34	343.630	344.060	344.017	USD -11,697	310.67 Loss of -1,134 on sale
2025-02-13	BUY	102	351.710	352.990	352.862	USD 35,992	308.21
2025-02-12	BUY	34	340.170	340.180	340.179	USD 11,566	307.55
2025-02-11	BUY	136	331.790	336.710	336.218	USD 45,726	307.05
2024-12-30	SELL	-1,160	311.620	315.270	314.905	USD -365,290	297.51 Loss of -20,174 on sale
2024-11-18	SELL	-555	303.490	308.430	307.936	USD -170,904	269.37 Loss of -21,401 on sale
2024-11-08	SELL	-37	350.700	357.050	356.415	USD -13,187	258.59 Loss of -3,620 on sale
2024-10-21	SELL	-37	208.890	213.020	212.607	USD -7,866	0.00 Loss of -7,866 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MDGL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	47,045	0	91,140	51.6%
2025-09-18	97,595	20	142,264	68.6%
2025-09-17	42,376	0	98,931	42.8%
2025-09-16	36,679	0	65,323	56.2%
2025-09-15	48,309	1,382	89,383	54.0%
2025-09-12	27,868	0	66,491	41.9%
2025-09-11	35,091	8	87,948	39.9%
2025-09-10	42,485	0	107,394	39.6%
2025-09-09	47,597	6	138,647	34.3%
2025-09-08	283,857	3,995	334,494	84.9%
2025-09-05	49,783	2,100	120,358	41.4%
2025-09-04	42,495	1,235	92,061	46.2%
2025-09-03	75,350	249	148,253	50.8%
2025-09-02	101,513	0	187,524	54.1%
2025-08-29	52,376	100	114,355	45.8%
2025-08-28	54,862	800	124,336	44.1%
2025-08-27	78,576	0	148,945	52.8%
2025-08-26	57,904	0	124,869	46.4%
2025-08-25	50,370	103	95,261	52.9%
2025-08-22	110,879	1,848	187,031	59.3%
2025-08-21	130,924	2,837	216,683	60.4%
2025-08-20	70,090	2,873	137,727	50.9%
2025-08-19	119,364	0	209,091	57.1%
2025-08-18	237,903	1,300	399,192	59.6%
2025-08-15	49,094	2,882	80,973	60.6%
2025-08-14	77,462	29	130,476	59.4%
2025-08-13	145,247	3,549	248,832	58.4%
2025-08-12	98,720	1,400	172,448	57.2%
2025-08-11	56,819	0	103,426	54.9%
2025-08-08	108,189	1,125	175,931	61.5%
2025-08-07	99,632	100	161,147	61.8%
2025-08-06	72,448	1	114,644	63.2%
2025-08-05	363,796	372	508,273	71.6%
2025-08-04	113,595	28	143,880	79.0%
2025-08-01	53,528	7	83,201	64.3%
2025-07-31	157,774	14	224,329	70.3%
2025-07-30	146,348	1	206,638	70.8%
2025-07-29	78,601	169	118,742	66.2%
2025-07-28	69,568	789	106,078	65.6%
2025-07-25	53,062	84	106,597	49.8%
2025-07-24	60,939	71	105,410	57.8%
2025-07-23	62,210	2	148,706	41.8%
2025-07-22	131,037	243	192,027	68.2%
2025-07-21	26,502	13	43,688	60.7%
2025-07-18	94,965	459	136,919	69.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE